相关实验视频

Updated: Jun 11, 2025

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

基于Olaparib和Rigosertib的双重向分子的发现,用于野生型BRCA三阴性乳腺癌

Zhikun Liu¹, Shining Mao¹, Lumei Dai²

¹Jiangsu Key Laboratory of Regional Specific Resource Pharmaceutical Transformation, Green Chemistry and Process Enhancement Technology, Huaiyin Institute of Technology, Huai'an 223003, China.

Bioorganic & medicinal chemistry

|October 6, 2024

概括

结合Olaparib和Rigosertib的新双向分子显示出治疗BRCA野生型三阴性乳腺癌 (TNBC) 的前景. 化合物13b表现出强大的抗瘤活性,并诱导亡,提供了潜在的新疗法策略.

科学领域:

在瘤学瘤学.
药用化学医学化学
药理学药理学是指药理学的学科.

背景情况:

PARP 抑制剂 (PARPis) 对 BRCA 突变的三阴性乳腺癌 (TNBC) 有效.
大多数TNBC患者缺乏BRCA突变,限制了PARPi的益处.
针对RAF-RAF等替代途径是新型抗TNBC药物的方法.

研究的目的:

为BRCA野生型TNBC开发新的双向分子.
为了整合Olaparib (PARPi) 和Rigosertib (RAF-RAF通路破坏者) 的药理.
评估TNBC模型中的抗增殖活性和治疗潜力.

主要方法:

合成双重向化合物,集成Olaparib和Rigosertib药.
在体外抗增殖测定对BRCA缺陷和野生型TNBC细胞.
在体内评估最佳化合物的抗瘤功效和毒性.

主要成果:

化合物13a-14c对TNBC细胞表现出抗增殖活性.
最佳化合物13b显示出强大的PARP-1抑制和诱导的亡.
与Olaparib和组合疗法相比,13b显示出更高的抗瘤疗效 (TGI 61.3%),没有显著的毒性.

结论:

化合物13b是治疗BRCA野生型TNBC的有希望的候选物.
双重准策略为更广泛的TNBC患者群体提供了潜在的治疗途径.
需要对13b进行进一步的BRCA野生型TNBC调查.

关键词:

双重目标分子的分子.三重阴性乳腺癌是什么?野生类型的BRCA.

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...